CEO of Pathway Therapeutics
Julie Cherrington, PhD is an accomplished life science executive with a record of demonstrated success in leading cutting-edge science into the clinic and beyond. Her experience and perspectives on the life science industry reach from the “bench to the boardroom”, with a keen focus on business results. Notably, Julie has the distinction of being a key contributor to the successful development of multiple FDA – approved products including anti-viral (Vistide‚Ñ¢, Viread‚Ñ¢, Hepsera‚Ñ¢) and anti-cancer agents (SUTENT‚Ñ¢, Palladia‚Ñ¢).
Most recently, Julie served as President and CEO of Pathway Therapeutics, an early stage bioscience company working on the discovery and development of novel targeted kinase inhibitors for the treatment of cancer, autoimmune and respiratory indications. Prior to joining Pathway, she served as President of Phenomix where she led diabetes and HCV research and development at the drug discovery, pre-clinical and clinical stages, and played a leadership role in financing and business development.
Prior to joining Phenomix in 2003, Julie was vice president of preclinical and clinical research at SUGEN, a Pfizer company, where she focused on the discovery and development of small molecule kinase inhibitors for the treatment of cancer and autoimmune diseases. Julie began her career developing antivirals at Gilead Sciences where she held a range of positions of increasing responsibility. She has served on the Boards of Directors of Chemgenex, Progen and Xenome. She serves on the Scientific Advisory Board of the Clearity Foundation.
Julie has a strong interest in the compelling challenges of early stage life science companies and is active as an advisor in university-based entrepreneurship initiatives, including the UC San Francisco Entrepreneurship Center, UCSF Catalyst, Stanford SPARK, UC Davis, as well as the BayBio Fellows All Star Team Advisory program.